Revolution Medicines, Inc. provided earnings guidance for full year 2024. For the year, the company expects GAAP net loss to be between $480 million and $520 million, which includes estimated non-cash stock-based compensation expense of between $70 million and $80 million. Based on the company?s current operating plan, the company projects current cash, cash equivalents and marketable securities can fund planned operations into 2027.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
38.88 USD | -0.44% | +4.29% | +35.56% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+35.56% | 6.63B | |
+21.74% | 46.4B | |
-0.97% | 41.75B | |
+49.62% | 41.37B | |
-3.52% | 29.71B | |
+11.12% | 26.01B | |
-19.37% | 19.52B | |
+31.18% | 12.43B | |
-0.04% | 12.13B | |
+0.39% | 12.18B |
- Stock Market
- Equities
- RVMD Stock
- News Revolution Medicines, Inc.
- Revolution Medicines, Inc. Provides Earnings Guidance for Full Year 2024